COVID 19 Supplement - NIH TCF TASK AREA B-1

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: JOHN  ALTMAN
Organization: EMORY UNIVERSITY
Fiscal Year: 2020
Award: $400,000
Funding agency: National Institute of Allergy and Infectious Diseases

The NIH Tetramer Core Facility (TCF) distributes high quality reagents for detection of innate T cell and classical CD4 and CD8 T cell populations. This Facility also conducts R&D to produce new reagents and improve existing tetramer technologies. The TCF is producing MHC class I and class II tetramers for isolation and characterization of SARS-CoV2-specific CD4 and CD8 T cells, and is also developing SARS-CoV-2 Spike protein tetramers for detection and characterization of SARS-CoV2 specific B cells. Thus far, 56 MHC tetramers have been distributed to the community, an additional 35 are in-process. Orders are expected to increase as COVID-related research increases. Additional reagents will be produced and distributed as new T cell epitopes and B cell antigen targets are identified. These tetramer reagents will be invaluable tools for evaluation of adaptive immune responses in COVID-19 patients or in response to candidate vaccines.

Terms: <2019 novel coronavirus><2019-nCoV><Antigen Targeting><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID><COVID-19><COVID19><Class I Genes><CoV disease><Communities><Core Facility><Detection><Development><Development and Research><Evaluation><MHC Class I><MHC Class I Genes><NIH><National Institutes of Health><Patients><Population><Process><Production><Proteins><R & D><R&D><Reagent><Research><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe acute respiratory syndrome coronavirus 2><T-Cell Epitopes><T-Cells><T-Lymphocyte><T-Lymphocyte Epitopes><T8 Cells><T8 Lymphocytes><Technology><United States National Institutes of Health><Wuhan coronavirus><adaptive immune response><corona virus disease><corona virus disease 2019><coronavirus disease><coronavirus disease 2019><developmental><improved><research and development><response><thymus derived lymphocyte><tool><vaccine candidate>